Interactions of organic anion transporters and organic cation transporters with mycotoxins

Journal of Pharmacological Sciences

Volumn 106, Issue 3, 2008, Pages 435-443

  Tachampa, Kittipong ^a,b   Takeda, Michio ^a   Khamdang, Suparat ^a,c   Noshiro Kofuji, Rie ^a   Tsuda, Minoru ^a   Jariyawat, Surawat ^b   Fukutomi, Toshiyuki ^a   Sophasan, Samaisukh ^b   Anzai, Naohiko ^a   Endou, Hitoshi ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MAHIDOL UNIVERSITY   (Thailand)

^c Ubon Rajathanee University   (Thailand)

Author keywords

Aflatoxin; Mycotoxin; Organic anion transporter; Organic cation transporter; SLC22

Indexed keywords

AFLATOXIN B1; ALPHA ZEARALENOL; CITRININ; CITRIOVERIDINE; MYCOTOXIN; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; TOXIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HUMAN; IC 50; KIDNEY; LIVER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT;

EID: 41549138734     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0070911     Document Type: Article

References (38)

1. Etzel RA. Mycotoxins. JAMA. 2002;287:425-427.
2. Pitt JI. Toxigenic fungi and mycotoxins. Br Med Bull. 2000;56:184-192.
3. van Montfoort JE, Hagenbuch B, Groothuis GM, Koepsell H, Meier PJ, Meijer DK. Drug uptake systems in liver and kidney. Curr Drug Metab. 2003;4:185-211.
4. Inui KI, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 2000;58:944-958.
5. Anzai N, Kanai Y, Endou H. Organic anion transporter family: current knowledge. J Pharmacol Sci. 2006;100:411-426.
6. Rizwan AN, Burckhardt G. Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res. 2007;24:450-470.
7. Burckhardt G. Polyspecific organic cation transport: insights into the substrate binding site. Mol Pharmacol. 2005;67:1391-1392.
8. You G. The role of organic ion transporters in drug disposition: an update. Curr Drug Metab. 2004;5:55-62.
9. Kontaxi M, Echkardt U, Hagenbuch B, Stieger B, Meier PJ, Petzinger E. Uptake of the mycotoxin ochratoxin A in liver cells occurs via the cloned organic anion transporting polypeptide. J Pharmacol Exp Ther. 1996;279:1507-1513.
10. Tsuda M, Sekine T, Takeda M, Cha SH, Kanai Y, Kimura M, et al. Transport of ochratoxin A by renal multispecific organic anion transporter 1. J Pharmacol Exp Ther. 1999;289:1301-1305.
11. Leier I, Hummel-Eisenbeiss J, Cui Y, Keppler D. ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int. 2000;57:1636-1642.
12. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, et al. Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001;69:2123-2135.
13. Babu E, Takeda M, Narikawa S, Kobayashi Y, Enomoto A, Tojo A, et al. Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochim Biophys Acta. 2002;590:64-75.
14. Hosoyamada M, Obinata M, Suzuki M, Endou H. Cisplatin-induced toxicity in immortalized renal cell lines established from transgenic mice harboring temperature sensitive SV40 large T-antigen gene. Arch Toxicol. 1996;70:284-292.
15. Hosoyamada M, Sekine T, Kanai Y, Endou H. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol. 1999;276:F122-F128.
16. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001;59:1277-1286.
17. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, et al. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002;300:918-924.
18. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H. Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem. 1997;272:18526-18529.
19. Enomoto A, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, Kobayashi Y, et al. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther. 2002;301:797-802.
20. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, et al. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999;274:13675-13680.
21. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, et al. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem. 2000;275:4507-4512.
22. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997;16:871-881.
23. Khamdang S, Takeda M, Narikawa S, Enomoto A, Anzai N, Piyachaturawat P, et al. Interactions of human organic anion transporters and human organic cation trasnporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002;303:534-539.
24. Takeda M, Narikawa S, Sekine T, Cha SH, Endou H. Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. Eur J Pharmacol. 2001;419:113-120.
25. Enomoto A, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, Kobayashi Y, et al. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther. 2002;301:797-802.
26. Hayer-Zillgen M, Bruss M, Bonisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002;136:829-836.
27. Carnaghan RBA, Hartley RD, O'Kelly J. Toxicity and fluorescence properties of the aflatoxins. Nature. 1963;200:1101-1102.
28. Van Rensburg SJ. Role of epidemiology in the evaluation of mycotoxin health risks. In: Rodericks JV, Hesseltine CW, Mehlam MA, editors. Mycotoxicosis in human and animal health. Park Forest South, IL: Pathtox; 1977. p. 699-711.
29. Newberne PM, Bulter WH. Acute and chronic effects of aflatoxin on the liver of domestic and laboratory animals: a review. Cancer Res. 1969;29:226-236.
30. Tandon BN, Krishnamurthy L, Koshy A, Tandon HD, Ramalingaswami V, Bhandari JR, et al. Study of an epidemic of jaundice, presumably due to toxic hepatitis, in Northwest India. Gastroenterol. 1977;72:488-494.
31. He X, Anzai N, Ueno T, Fukutomi T, Sakata T, Endou H, et al. Transport of nicotinate by human organic anion transporter hOAT2 and its possible interaction with transport of salicylate. J Pharmacol Sci. 2006;100 Suppl I:126P.
32. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997;51:913-921.
33. Becroft DM, Webster DR. Aflatoxins and Reye's disease. Br Med J. 1972;4:117.
34. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001;59:1277-1286.
35. Alebouyeh M, Takeda M, Onozato ML, Tojo A, Noshiro R, Hasannejad H, et al. Expression of human organic anion transporters in the choroid plexus and their interactions with neurotransmitter metabolites. J Pharmacol Sci. 2003;93:430-436.
36. Phillips RD, Haynes AW, Berndt WO, Williams WL. Effects of citrinin on function and structure. Toxicology. 1983;16:123-127.
37. Hard GC, Howard PC, Kovatch RM, Bucci TJ. Rat kidney pathology induced by chronic exposure to fumonisin B1 includes rare variants of renal tubule tumor. Toxicol Pathol. 2001;29:379-386.
38. Loe DW, Stewart RK, Massey TE, Deeley RG, Cole S. ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol Pharmacol. 1997;51:1034-1041.